Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$32.80

-0.75 (-2.24%)

16:17
08/14/18
08/14
16:17
08/14/18
16:17

Biohaven Pharmaceutical reports Q2 EPS ($1.01), consensus ($1.18)

Reports Q2 revenue $0, consensus $0. Reports cash as of June 30 $217.5M, compared to $104.2M as of March 31. This increase primarily reflects the net proceeds of approximately $149.6M from the Company's transaction with Royalty Pharma, offset by payments for operating expenses during the quarter.

  • 30

    Aug

  • 31

    Aug

BHVN Biohaven Pharmaceutical
$32.80

-0.75 (-2.24%)

06/11/18
CANT
06/11/18
INITIATION
Target $42
CANT
Overweight
Biohaven Pharmaceutical initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Biohaven Pharmaceuticals with a Overweight and $42 price target.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
06/19/18
LEHM
06/19/18
NO CHANGE
Target $40
LEHM
Equal Weight
Biohaven price target raised to $40 from $25 at Barclays
Barclays analyst Geoff Meacham raised his price target for Equal Weight-rated Biohaven Pharmaceutical to $40 after reassessing the clinical risk for the company's later-stage program in acute migraine. The analyst now sees a "relatively high" probability of success for rimegepant and slightly higher platform value. The next key value creating point for the company will be the eventual launch, which is not expected until 2020, Meacham tells investors in a research note. As such, he thinks fair value of the acute migraine program, with additional credit to the broader development platform, is accurately reflected in Biohaven's share price.
07/12/18
CANT
07/12/18
NO CHANGE
Target $50
CANT
Overweight
Biohaven price target raised to $50 from $42 at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes raised his price target for Biohaven Pharmaceutical to $50 and reaffirms an Overweight rating on the shares after meeting this week with CEO Vlad Coric and CFO Jim Engelhart. The Street's focus on rimegepant acute oral calcitonin gene-related peptide data has led to an "under-appreciation of Biohaven's other opportunities to drive long term share holder value beyond current levels," Folkes tells investors in a research note. The analyst sees "multiple catalysts" keeping momentum in the stock through 2018 and 2019.

TODAY'S FREE FLY STORIES

APHB

AmpliPhi

$0.16

-0.0264 (-14.13%)

06:52
12/18/18
12/18
06:52
12/18/18
06:52
Hot Stocks
AmpliPhi announces scales up manufacturing process for AB-SA01 »

AmpliPhi Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEI

Douglas Emmett

$34.06

-1.39 (-3.92%)

06:52
12/18/18
12/18
06:52
12/18/18
06:52
Downgrade
Douglas Emmett rating change  »

Douglas Emmett downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSC

Norfolk Southern

$147.63

-3.18 (-2.11%)

06:52
12/18/18
12/18
06:52
12/18/18
06:52
Upgrade
Norfolk Southern rating change  »

JPMorgan upgrades Norfolk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$108.36

-3.59 (-3.21%)

06:51
12/18/18
12/18
06:51
12/18/18
06:51
Hot Stocks
Eli Lilly announces subgroup data from MONARCH 2, MONARCH 3 trials published »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

LXFR

Luxfer

$21.42

-1.26 (-5.56%)

06:50
12/18/18
12/18
06:50
12/18/18
06:50
Conference/Events
Luxfer to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

ELY

Callaway Golf

$15.53

-1.11 (-6.67%)

06:50
12/18/18
12/18
06:50
12/18/18
06:50
Upgrade
Callaway Golf rating change  »

Callaway Golf upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$95.83

-0.86 (-0.89%)

06:48
12/18/18
12/18
06:48
12/18/18
06:48
Downgrade
Kansas City Southern rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGTI

PGT Innovations

$16.18

-0.23 (-1.40%)

06:45
12/18/18
12/18
06:45
12/18/18
06:45
Initiation
PGT Innovations initiated  »

PGT Innovations initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$198.63

-6.71 (-3.27%)

, INFO

IHS Markit

$48.56

-0.27 (-0.55%)

06:45
12/18/18
12/18
06:45
12/18/18
06:45
Recommendations
Cigna, IHS Markit, Humana analyst commentary  »

Cigna, IHS Markit added…

CI

Cigna

$198.63

-6.71 (-3.27%)

INFO

IHS Markit

$48.56

-0.27 (-0.55%)

HUM

Humana

$303.84

3.43 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

  • 10

    Jan

  • 15

    Jan

PM

Philip Morris

$81.39

-1.15 (-1.39%)

, BTI

British American Tobacco

$32.73

-0.36 (-1.09%)

06:42
12/18/18
12/18
06:42
12/18/18
06:42
Downgrade
Philip Morris, British American Tobacco, Imperial Brands rating change  »

Philip Morris downgraded…

PM

Philip Morris

$81.39

-1.15 (-1.39%)

BTI

British American Tobacco

$32.73

-0.36 (-1.09%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 16

    Jan

  • 17

    Jan

CTRP

Ctrip

$27.31

-0.86 (-3.05%)

06:42
12/18/18
12/18
06:42
12/18/18
06:42
Periodicals
Ctrip CEO says U.S. trade dispute impacted tourism, FT reports »

Ctrip CEO Jane Sun said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

NAV

Navistar

$23.84

-1.93 (-7.49%)

06:37
12/18/18
12/18
06:37
12/18/18
06:37
Earnings
Navistar sees FY19 revenue $10.75B-$11.25B, consensus $10.57B »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

GD

General Dynamics

$163.43

-5.47 (-3.24%)

06:36
12/18/18
12/18
06:36
12/18/18
06:36
Periodicals
General Dynamics warns Canada over scrapping Saudi deal, Reuters reports »

General Dynamics Canadian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DPW

DPW Holdings

$0.14

-0.0138 (-9.21%)

06:34
12/18/18
12/18
06:34
12/18/18
06:34
Hot Stocks
DPW Holdings authorizes pursuit of IPO for DPW Technology Group »

DPW Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$23.84

-1.93 (-7.49%)

06:34
12/18/18
12/18
06:34
12/18/18
06:34
Earnings
Navistar reports Q4 EPS $1.89, consensus $1.71 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CNCE

Concert Pharmaceuticals

$13.69

0.16 (1.18%)

, ACRS

Aclaris Therapeutics

$6.99

-0.31 (-4.25%)

06:33
12/18/18
12/18
06:33
12/18/18
06:33
Recommendations
Concert Pharmaceuticals, Aclaris Therapeutics analyst commentary  »

Concert remains…

CNCE

Concert Pharmaceuticals

$13.69

0.16 (1.18%)

ACRS

Aclaris Therapeutics

$6.99

-0.31 (-4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPK

Chesapeake Utilities

$87.88

-5.12 (-5.51%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Chesapeake Utilities subsidiary acquires propane operating assets in PA »

Chesapeake Utilities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMSI

Smith Micro

$1.97

-0.11 (-5.29%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Smith Micro to acquire ISM Connect Smart Retail suite for $9.8M »

Smith Micro Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$5.94

0.08 (1.37%)

, GSK

GlaxoSmithKline

$37.07

-0.54 (-1.44%)

06:32
12/18/18
12/18
06:32
12/18/18
06:32
Hot Stocks
Epizyme earns $8M milestone payment from GlaxoSmithKline »

Epizyme (EPZM) announced…

EPZM

Epizyme

$5.94

0.08 (1.37%)

GSK

GlaxoSmithKline

$37.07

-0.54 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

06:29
12/18/18
12/18
06:29
12/18/18
06:29
Downgrade
Flowserve rating change  »

Flowserve downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$128.13

-2.89 (-2.21%)

06:29
12/18/18
12/18
06:29
12/18/18
06:29
Downgrade
Illinois Tool Works rating change  »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBB

Hubbell

$102.51

-0.405 (-0.39%)

06:28
12/18/18
12/18
06:28
12/18/18
06:28
Downgrade
Hubbell rating change  »

Hubbell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:27
12/18/18
12/18
06:27
12/18/18
06:27
Periodicals
Nissan CEO to meet with Renault boss in Amsterdam, Reuters reports »

Nissan (NSANY) CEO Hiroto…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

HST

Host Hotels

$17.31

-0.46 (-2.59%)

06:21
12/18/18
12/18
06:21
12/18/18
06:21
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSA

Public Storage

$199.42

-4.07 (-2.00%)

06:20
12/18/18
12/18
06:20
12/18/18
06:20
Upgrade
Public Storage rating change  »

Public Storage upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.